Sign In
Buy ICCM
$0.152
+0.0127 (+9.14%)
At Close: Jun 03, 2026
IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024
08:30am, Tuesday, 13'th Aug 2024
CAESAREA, Israel , Aug. 13, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing
Investigator initiated independent study included higher risk patients such as those with metastatic disease, large tumors, and comorbidities, as compared to IceCure's ICE3 study which treated early-
Demand for minimally invasive breast cancer treatment was overarching theme of the conference In one independent study led by Professor Fukuma, 389 patients treated for up to 10 years had 99.74% recur
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
04:30pm, Friday, 19'th Jul 2024
CAESAREA, Israel , July 19, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alt
IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint
02:25pm, Thursday, 11'th Jul 2024
IceCure Medical Ltd. ICCM recently announced the publication of data from an independent study evaluating its ProSense cryoablation system in the peer-reviewed journal — Cancers.
Independent, third-party data published in highly influential peer-reviewed journal, Cancers, concluded cryoablation with ProSense® is a safe, local treatment for breast cancer with low complication
IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod
12:50pm, Wednesday, 03'rd Jul 2024
IceCure Medical Ltd ICCM recently announced that it has received marketing authorization from the FDA for its next-generation single probe cryoablation system, XSense Cryoablation System with CryoPr
CAESAREA, Israel , July 1, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destr
Recent insider open-market stock purchases demonstrate continued confidence in the Company CAESAREA, Israel , June 18, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure M
ICESECRET interim results, as previously announced, demonstrated ProSense® to be safe and effective in treating kidney tumors with 89.5% recurrence-free rate More data is expected in the fourth quart
IceCure Medical (ICCM) Moves to Buy: Rationale Behind the Upgrade
01:01pm, Tuesday, 04'th Jun 2024
IceCure Medical (ICCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Demonstrates public health importance of assessing ProSense®'s potential to offer optimal treatment that benefits women with early-stage breast cancer Patients, patient advocacy groups, doctors, and
IceCure Medical Ltd (ICCM) Q1 2024 Earnings Call Transcript
05:06pm, Tuesday, 28'th May 2024
IceCure Medical Ltd (NASDAQ:ICCM ) Q1 2024 Earnings Conference Call May 28, 2024 11:00 AM ET Company Participants Michael Polyviou - Investor Relations Eyal Shamir - Chief Executive Officer Tlalit Bus
IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024
08:30am, Tuesday, 28'th May 2024
30% sales growth reflects continued adoption of ProSense® in the U.S. and other global markets Major milestones achieved: - Completion of landmark ICE3 trial for breast cancer - Positive final ICE3
IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024
08:53am, Tuesday, 21'st May 2024
CAESAREA, Israel, May 21, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that
